1.89
+0.02(+1.07%)
Currency In USD
| Previous Close | 1.87 |
| Open | 1.9 |
| Day High | 1.95 |
| Day Low | 1.87 |
| 52-Week High | 2.82 |
| 52-Week Low | 1.41 |
| Volume | 124,718 |
| Average Volume | 595,257 |
| Market Cap | 67.94M |
| PE | -3.2 |
| EPS | -0.59 |
| Moving Average 50 Days | 1.79 |
| Moving Average 200 Days | 1.92 |
| Change | 0.02 |
If you invested $1000 in Gain Therapeutics, Inc. (GANX) since IPO date, it would be worth $153.28 as of October 20, 2025 at a share price of $1.87. Whereas If you bought $1000 worth of Gain Therapeutics, Inc. (GANX) shares 3 years ago, it would be worth $603.23 as of October 20, 2025 at a share price of $1.87.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Gain Therapeutics to Attend the 2025 Maxim Growth Summit
GlobeNewswire Inc.
Oct 16, 2025 11:00 AM GMT
BETHESDA, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule the
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
GlobeNewswire Inc.
Oct 09, 2025 11:00 AM GMT
Event to be held October 14th at 4 p.m. ESTBETHESDA, Md., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders®
GlobeNewswire Inc.
Oct 06, 2025 12:15 PM GMT
Improvement observed in MDS-UPDRS scores in first 9 participants enrolled; 90-day follow-up continuing in remaining participants Plasma exposures in patients within projected therapeutic range and comparable to exposures observed in Phase 1 healthy v